Harrow Health Inc

Harrow Health Inc. an eyecare pharmaceutical company focuses on the discovery development and commercialization of ophthalmic therapies. The company offers ImprimisRx an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe; TRIESENCE a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100 a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Imprimis Pharmaceuticals Inc. and changed its name to Harrow Health Inc. in December 2018. Harrow Health Inc. was founded in 1998 and is headquartered in Nashville Tennessee.